血管压素在心脏手术后高压阻塞性心肌病症中的作用:一个病例报告
Dimitrios Elaiopoulos1, Fotios Dimitriadis1, Eleni Tzatzaki1
1Cardiac Surgery Intensive Care Unit, Onassis Cardiac Surgery Center, Athens 17674, Attikí, Greece.
World journal of critical care medicine
|December 11, 2025
概括
血管压素有效地管理心脏手术后的左心室外流通道阻塞 (LVOTO) 和静脉前运动 (SAM). 这种血管压缩剂与其他药物不同,缺乏内效应,有助于患者的稳定.
科学领域:
- 心脏病学 心脏病学
- 心血管外科心血管外科
- 临界护理医学 临界护理医学
背景情况:
- 控制左心室外流管阻塞 (LVOTO) 和静心前运动 (SAM) 在心脏手术后带来了挑战,特别是在循环休克和肺时.
- 这些情况可能会使重症监护室 (ICU) 的康复复复杂化.
研究的目的:
- 关于在心脏手术后经历循环休克的患者中管理LVOTO和SAM的案例研究.
- 在这种特定的临床场景中评估血管压素作为血管压缩剂的疗效.
主要方法:
- 一份病例报告显示,一名80岁的女性患有严重的大动脉狭窄和超大缩性阻塞性心肌病,正在接受大动脉置换和肌切除术.
- 管理涉及双室节奏,上腺素,富洛西米德,埃斯莫洛尔和通风,然后再添加血管压素.
- 跨胸腔心声扫描用于诊断和监测.
主要成果:
- 患者最初在血液动力学上恶化了,尽管服用诺拉上腺素,但患有低氧化和肺.
- 添加血管压素和逐渐减小诺拉上腺素导致患者的稳定.
- 观察到LVOTO显著减少,氧化改善,尿液输出增加.
结论:
- 血管压素是LVOTO和SAM心脏手术后的首选血管压缩剂,因为它缺乏内效应.
- 心声谱在这些疾病的早期诊断和治疗管理中起着至关重要的作用.
相关概念视频
Cardiomyopathy VII: Pre and Post Operative Nursing Management
257
Patients with hypertrophic cardiomyopathy (HCM) and left ventricular outflow tract (LVOT) obstruction who remain symptomatic despite optimal medical therapy may undergo a septal myectomy (Morrow procedure). This procedure involves excising a portion of the hypertrophied septum below the aortic valve using a heart-lung machine to improve blood flow through the LVOT. Effective preoperative and postoperative nursing management ensures successful patient outcomes, minimizes complications, and...
257
Cardiomyopathy V: Interprofessional Care
313
Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...
313
Cardiomyopathy III: Hypertrophic Cardiomyopathy
362
Hypertrophic cardiomyopathy, or HCM, is an autosomal dominant genetic disorder characterized by asymmetric left ventricular hypertrophy without ventricular dilation. It is more common in men and is typically diagnosed in young, athletic adults.EtiologyHCM is primarily genetic and is caused by mutations in genes encoding sarcomeric proteins. Researchers have identified over 1400 mutations across at least 11 different genes. Among these, the most frequently occurring mutations are found in the...
362
Heart Failure II: Pathophysiology
668
Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
668
Cardiomyopathy II: Dilated Cardiomyopathy
436
Dilated cardiomyopathy, or DCM, is a progressive myocardial disorder characterized by ventricular chamber dilation and contractile dysfunction.EtiologyVarious factors can cause DCM, including hypertension and heavy alcohol intake, which contribute to the weakening and enlargement of the heart muscle. Viral infections, such as Coxsackievirus B, adenoviruses, and influenza, can lead to DCM by causing inflammation and damage to heart tissue. Certain chemotherapeutic agents, including daunorubicin,...
436
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
879
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
879


